BofA Securities Downgrades Intellia Therapeutics (NTLA) to Neutral, 'FDA pause lowers contribution from key value driver'
Tweet Send to a Friend
BofA Securities analyst Greg Harrison downgraded Intellia Therapeutics (NASDAQ: NTLA) from Buy to Neutral with a price target of $14.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
